Patent expiries take chunk out of Lilly’s profits

24-07-2014

Patent expiries take chunk out of Lilly’s profits

Katherine Welles / Shutterstock.com

A 17 percent fall in Eli Lilly’s second-quarter revenue to $4.94 billion, reported today (July 24), was driven by the expiry of US patents covering antidepressant Cymbalta (duloxetine hydrochloride) and osteoporosis drug Evista (raloxifene hydrochloride), the company said.


Eli Lilly, patent expiry, patent cliff, Cymbalta, Evista

LSIPR